Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD4818 · 1 trial · 1 indication
Number of patients who had an Adverse Event
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | AZD4818 |
| 2 | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| AZD4818 | DRUG | Dry Powder, inhalation, b.i.d., 4 weeks |
| Placebo | DRUG | - |
Inclusion Criteria: * Clinical diagnosis of COPD, with symptoms for more than 1 year * Current or ex-smokers with a smoking history of at least 10 pack-years (1 pack-year=20 cigarettes/day for 1 year) * Lung function (FEV1) 40 to 80% of the predicted normal value after using a short acting bronchod...
AZD4818 was developed for the treatment of moderate to severe chronic obstructive pulmonary disease (COPD). It was studied as an inhaled therapy in adults aged 40 years and older with COPD. The compound is a small molecule and was investigated in a Phase 2 clinical trial.
AZD4818 targets CCR1, a chemokine receptor. It acts as a CCR1 antagonist, meaning it blocks the receptor rather than activating it. By targeting CCR1, the drug was designed to interfere with inflammatory signaling pathways relevant to COPD. The compound is a small molecule administered by inhalation.
AZD4818 was developed by AstraZeneca PLC, which trades under the ticker AZN. AstraZeneca sponsored the clinical trial of AZD4818 in patients with COPD. The company is a global biopharmaceutical developer headquartered in the United Kingdom.
AZD4818 is in Phase 2 development. It has been evaluated in a completed Phase 2 clinical trial in patients with moderate to severe COPD. The drug is investigational and has not been approved for any indication. No active trials of AZD4818 are currently listed.
AZD4818 has been studied in one completed Phase 2 trial, NCT00629239, titled Tolerability/Safety and Efficacy of Inhaled AZD4818 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD). The trial enrolled 65 participants across Denmark, Finland, Netherlands, Norway, and Sweden. It was randomized, double-blind, and placebo-controlled.